-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 16, Eli Lilly announced that the US FDA has expanded its new coronavirus neutralizing antibodies bamlanivimab (700mg) and etesevimab (1400mg) emergency use authorization (EUA) in cooperation with Junshi for post-exposure prevention (PEP)
FDA prevents COVID-19 immune infection
This expanded authorization is based on data from BLAZE-2
bamlanivimab (LY-CoV555) was discovered by AbCellera and developed by Eli Lilly.
etesevimab (JS016 or LY-CoV016) is a recombinant fully human monoclonal neutralizing antibody that specifically binds to the receptor binding domain of the spike protein on the surface of SARS-CoV-2 with high affinity, and can effectively block the virus and host cells Binding of the surface receptor ACE2
On June 25, 2021, the U.
Leave a message here